Cover image
市場調查報告書 - 227860

全球肌肉骨骼疾病治療藥物的市場(到2017年為止)

Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014

出版商 GBI Research
出版日期 2012年01月06日 內容資訊 英文 159 Pages
價格
全球肌肉骨骼疾病治療藥物的市場(到2017年為止) Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014
出版日期: 2012年01月06日 內容資訊: 英文 159 Pages
簡介

本報告提供全球肌肉骨骼疾病的相關市場分析,最新研究開發、全球及主要國家市場趨勢、主要疾患單位的詳細市場結構與動向、主要企業簡介、企業間合作的實情等資訊,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 市場概況

  • 簡介
    • 收益
    • 年度治療費用
    • 治療藥物的利用模式

第4章 各地區情形

  • 地區區分
  • 美國
    • 收益
    • 年度治療費用
    • 治療藥物的利用模式
  • 歐洲(前5個國家)
    • 收益
    • 年度治療費用
    • 治療藥物的利用模式
  • 日本
    • 收益
    • 年度治療費用
    • 治療藥物的利用模式

第5章 各個治療藥物的市場概況

  • 風濕性關節炎治療藥物的全球市場
    • 簡介
    • 收益
    • 年度治療費用
    • 治療藥物的利用模式
    • 治療流程的研究
    • 推動及阻礙市場要素
  • 骨質疏鬆症治療藥物的全球市場
    • 簡介
    • 收益
    • 年度治療費用
    • 治療藥物的利用模式
    • 治療流程的研究
    • 推動及阻礙市場要素
  • 骨關節炎治療藥物的全球市場
    • 簡介
    • 收益
    • 年度治療費用
    • 治療藥物的利用模式
    • 治療流程的研究
    • 推動及阻礙市場要素
  • 腰痛治療藥物的全球市場
    • 簡介
    • 收益
    • 年度治療費用
    • 治療藥物的利用模式
    • 治療流程的研究
    • 推動及阻礙市場要素
  • 肌肉營養不良症治療藥物的全球市場
    • 簡介
    • 收益
    • 年度治療費用
    • 治療藥物的利用模式
    • 治療流程的研究
    • 推動及阻礙市場要素

第6章 開發平台分析

  • 簡介
  • 各臨床實驗階段的開發平台評估
    • 登記完畢的分子
    • 階段III
    • 階段II
    • 階段I
    • 前臨床
    • 藥物發明
  • 有前途的分子簡介
    • YM529 (minodronate)
    • EX101 (alendronate)
    • MAbThera (rituximab)
    • Actemra (tocilizumab)
    • Simponi
    • Naproxcinod
    • Iguratimod

第7章 競爭環境

  • 主要企業簡介
    • Abbott Laboratories
    • Johnson & Johnson
    • Amgen Inc.
    • Pfizer Inc
    • Eli Lilly and Company

第8章 策略性的企業整合

  • 企業合併·收購
  • 共同開發契約
  • 許可證交易

第9章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Abstract

Summary

GBI Research's analysis shows that the overall global musculoskeletal disorders therapeutics market for the five indications (which includes rheumatoid arthritis, osteoporosis, osteoarthritis, low back pain and muscular dystrophy) was valued at $33.4 billion in 2010, indicating a CAGR of 5.7% over the previous year. GBI Research forecasts the market to grow at a CAGR of 7.3% between 2010 and 2017, to record a sales value of $54.8 billion by 2017. The growth in major markets such as the US and the top five countries in the EU and Japan were driven by new developments that created more options in the treatment of rheumatoid arthritis, osteoporosis, osteoarthritis, muscular dystrophy and low back pain. The global musculoskeletal disorders market is expected to witness a series of patent expiries between 2010 and 2017, which includes some top selling drugs such as Cymbalta (duloxetine HCl) and Celebrex (celecoxib). The future of the market is based on the success of the drugs in the pipeline; while the current musculoskeletal disorders market pipeline holds strong prospects for growth in the future, these factors will not be able to completely offset the challenge from generic competition. Muscular dystrophy is one of the most commonly recognized musculoskeletal disorders, but there are no approved therapeutic options available for this disease. For this reason, the generic share continues to rise in the market.

Scope

  • Data and analysis on the musculoskeletal disorders therapeutics market in the leading geographies of the world - the US, the UK, Germany, France, Italy, Spain, and Japan.
  • Annualized market data for the market from 2002 to 2010, with forecasts to 2017 for the three indications - rheumatoid arthritis, osteoporosis, osteoarthritis, low back pain and muscular dystrophy.
  • Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
  • Share of the generics in the global musculoskeletal disorders therapeutics market and for the market of each indication that is covered in the report.
  • Key drivers and restraints that have had a significant impact on the market.
  • The competitive landscape of the market, including top companies benchmarking. The key companies studied in this report are Pfizer Inc., Eli Lilly, Johnson & Johnson, Amgen Inc. and Abbott Laboratories.
  • Key M&A activities and Licensing Agreements that took place in 2009 and 2011 in the musculoskeletal disorders therapeutics market.

Reasons to buy

  • Align your product portfolio to the markets with high growth potential.
  • Build effective strategies to launch their pipeline products by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of top competitors.
  • Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

Executive Summary

GBI Research, the leading business intelligence provider, has released its latest report, “Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014”. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of the major musculoskeletal disorders, including rheumatoid arthritis, osteoporosis, osteoarthritis, low back pain and muscular dystrophy. The report also provides the share of generics in the global musculoskeletal disorders as well as in each indication market. It also provides the treatment flow algorithm for each of the five indications. The report examines the global musculoskeletal disorders treatment usage patterns. In addition, our research details the geographical distribution of musculoskeletal disorders markets across the US, the top five countries of Europe, and Japan.The report also includes insight into the musculoskeletal disorders R&D product pipeline and explores the competitive landscape, including major players in the musculoskeletal disorders therapeutics market. Finally, the report includes analysis of Mergers and Acquisitions (M&As) and licensing agreements that took place in the musculoskeletal disorders therapeutics market in recent years.

Global Musculoskeletal Disorders Therapeutics Market to Witnesses Moderate Growth as Generic Share Continues to Rise

In 2010, the global musculoskeletal disorders market was approximately $33.4 billion, representing a compound annual growth rate (CAGR) of 5.7% between 2002 and 2010. By 2017, the global market is estimated to reach $54.8 billion, indicating a CAGR of 7.3% between 2010 and 2017. The major reason behind the growth rate is the approval of Prolia (denosumab) during 2010. Although the market for management is highly competitive, blockbuster sales of Cymbalta (duloxetine HCl) coupled with improved diagnosis is expected to drive the market in the future.

The global musculoskeletal disorders market is expected to witness a series of patent expiries between 2010 and 2017, which includes some top selling drugs such as Cymbalta (duloxetine HCl) and Celebrex (celecoxib). While the current market pipeline has a prospect for growth in the future, these factors will not be able to completely offset the challenge from generic competition. Muscular dystrophy is one of the most commonly recognized musculoskeletal disorders, but there are no approved therapeutic options available for this disease. For this reason, the market's generic share continues to rise.

The Musculoskeletal Disorders Therapeutics Market is Concentrated with the Top Three Companies contributing approximately 45% of the Market Share

The global musculoskeletal disorders therapeutics market is dominated by three major pharmaceutical companies that account for approximately 43% of the total share of this market. The major market share is occupied by Abbott, followed by Johnson & Johnson and Amgen. The presence of various large as well as small pharmaceutical companies makes this market strong in terms of competition. However, the presence of blockbuster drugs has made these three companies the dominant players in this market. Abbott with Humira, the drug for rheumatoid arthritis, stands first with total revenues of $6.5 billion. Remicade, the drug used to treat rheumatoid arthritis, has made Johnson & Johnson the second largest player in the market with total revenues of $4.6 billion. Amgen, with rheumatoid arthritis drug, Enbrel occupies the third position in terms of market share with total revenues of $3.5 billion for the musculoskeletal disorder therapeutics market. This shows that the market is highly concentrated, leaving only 55% of the market open for other players to operate.

Unmet Need for Better Management of Musculoskeletal Diseases and Potential for Future Growth is Driving Companies to Invest in Research and Development

The research and development (R&D) pipeline for musculoskeletal disorders diseases is moderately healthy due to the presence of about 468 programs. These programs study drug candidates for the treatment of musculoskeletal disorders associated with osteoarthritis, osteoporosis, rheumatoid arthritis, low back pain and muscular dystrophy. However, the products in the pipeline do not look especially promising and may not provide better efficacy or safety levels compared to the drugs currently in the market. The pipeline consists of both first-in-class and 'me-too' products. The success of the first-in-class products will determine the future prospects for the industry. The high R&D activity indicates that the musculoskeletal disorders market has good potential for growth.

The musculoskeletal disorders market is marked by the extensive availability of generic drugs. The market will be considerably impacted by the patent expiries of several major drugs such as Cymbalta, Humira and Cerebrex. Another trend shaping the musculoskeletal disorders market worldwide is considerable M&A activity and licensing agreements among drug delivery firms; leading pharmaceutical companies are expected to develop tamper and abuse-resistant novel drug innovations in the forecast period.

Table of Contents

1. Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2. Musculoskeletal Disorders Therapeutics Market to 2017 -Introduction

  • 2.1 GBI Research Report Guidance

3. Musculoskeletal Disorders Therapeutics Market to 2017 - Market Overview

  • 3.1 Introduction
    • 3.1.1 Revenue
    • 3.1.2 Annual Cost of Treatment
    • 3.1.3 Treatment Usage Pattern

4. Musculoskeletal Disorders Therapeutics Market to 2017 -Geographical Landscape

  • 4.1 Revenue Analysis by Geography
  • 4.2 The US
    • 4.2.1 Revenue
    • 4.2.2 Annual Cost of Treatment
    • 4.2.3 Treatment Usage Patterns
  • 4.3 Top Five Countries of Europe
    • 4.3.1 Revenue
    • 4.3.2 Annual Cost of Treatment
    • 4.3.3 Treatment Usage Patterns
  • 4.4 Japan
    • 4.4.1 Revenue
    • 4.4.2 Annual Cost of Treatment
    • 4.4.3 Treatment Usage Patterns

5. Musculoskeletal Disorders Therapeutics Market to 2017 - Therapeutic Landscape

  • 5.1 Rheumatoid Arthritis Therapeutics Market
    • 5.1.1 Introduction
    • 5.1.2 Revenue
    • 5.1.3 Annual Cost of Treatment
    • 5.1.4 Treatment Usage Pattern
    • 5.1.5 Treatment Flow Algorithm
    • 5.1.6 Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market
  • 5.2 Osteoporosis Therapeutics
    • 5.2.1 Introduction
    • 5.2.2 Revenue
    • 5.2.3 Annual Cost of Treatment
    • 5.2.4 Treatment Usage Patterns
    • 5.2.5 Treatment Flow Algorithm
    • 5.2.6 Drivers and Barriers for Osteoporosis Therapeutics Market
  • 5.3 Osteoarthritis Therapeutics
    • 5.3.1 Introduction
    • 5.3.2 Revenue
    • 5.3.3 Annual Cost of Treatment
    • 5.3.4 Treatment Usage Patterns
    • 5.3.5 Treatment Flow Algorithm
    • 5.3.6 Drivers and Barriers for Osteoarthritis Therapeutics Market
  • 5.4 Low Back Pain Therapeutics
    • 5.4.1 Introduction
    • 5.4.2 Revenue
    • 5.4.3 Annual Cost of Treatment
    • 5.4.4 Treatment Usage Patterns
    • 5.4.5 Treatment Flow Algorithm
    • 5.4.6 Drivers and Barriers for Low Back Pain Therapeutics Market
  • 5.5 Muscular Dystrophy Therapeutics
    • 5.5.1 Introduction
    • 5.5.2 Revenue
    • 5.5.3 Annual Cost of Treatment
    • 5.5.4 Treatment Usage Patterns
    • 5.5.5 Treatment Flow Algorithm
    • 5.5.6 Drivers and Barriers for Muscular Dystrophy Therapeutics Market

6. Musculoskeletal Disorders Therapeutics Market to 2017 - Pipeline Analysis

  • 6.1 Introduction
  • 6.2 Musculoskeletal Disorders Therapeutics Market - Pipeline Assessment by Clinical Phase of Development
    • 6.2.1 NDA Filed Molecules
    • 6.2.2 Phase III
    • 6.2.3 Phase II
    • 6.2.4 Phase I
    • 6.2.5 Preclinical Phase
    • 6.2.6 Discovery Phase
  • 6.3 Profiles of Promising Molecules in the Musculoskeletal Disorders Therapeutics Market
    • 6.3.1 YM529 (minodronate)
    • 6.3.2 EX101 (alendronate)
    • 6.3.3 MAbThera (rituximab)
    • 6.3.4 Actemra (tocilizumab)
    • 6.3.5 Simponi
    • 6.3.6 Naproxcinod
    • 6.3.7 Iguratimod

7. Musculoskeletal Disorders Therapeutics Market to 2017 - Competitive Profiling

  • 7.1 Competitive Profiling
    • 7.1.1 Abbott Laboratories
    • 7.1.2 Johnson & Johnson
    • 7.1.3 Amgen Inc.
    • 7.1.4 Pfizer Inc
    • 7.1.5 Eli Lilly and Company

8. Musculoskeletal Disorders Therapeutics Market to 2017 - Strategic Consolidations

  • 8.1 Mergers and Acquisitions
    • 8.1.1 Segmentation by Deal Value
    • 8.1.2 Segmentation by Geography
  • 8.2 Co-development Deals
    • 8.2.1 Summary of Co-development Deals
  • 8.3 Licensing Deals
    • 8.3.1 Summary of Licensing Deals

9. Musculoskeletal Disorders Therapeutics Market to 2017 - Appendix

  • 9.1 Market Definitions
  • 9.2 Abbreviations
  • 9.3 Research Methodology
    • 9.3.1 Coverage
    • 9.3.2 Secondary Research
    • 9.3.3 Primary Research
  • 9.4 Therapeutic Landscape
    • 9.4.1 Epidemiology-based Forecasting
    • 9.4.2 Market Size by Geography
  • 9.5 Geographical Landscape
  • 9.6 Pipeline Analysis
  • 9.7 Competitive Landscape
    • 9.7.1 Expert Panel Validation
  • 9.8 Contact Us
  • 9.9 Disclaimer
  • 9.10 Sources

List of Tables

  • Table 1: Musculoskeletal Disorders Therapeutics Market, Global, Revenue ($bn), 2002-2010
  • Table 2: Musculoskeletal Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017
  • Table 3: Musculoskeletal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
  • Table 4: Musculoskeletal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017
  • Table 5: Musculoskeletal Disorders Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010
  • Table 6: Musculoskeletal Disorders Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2017
  • Table 7: Musculoskeletal Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010
  • Table 8: Musculoskeletal Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017
  • Table 9: Musculoskeletal Disorders Therapeutics Market, The US, Revenue ($bn), 2002-2010
  • Table 10: Musculoskeletal Disorders Therapeutics Market, The US, Revenue Forecasts ($bn), 2010-2017
  • Table 11: Musculoskeletal Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2002-2010
  • Table 12: Musculoskeletal Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2010-2017
  • Table 13: Musculoskeletal Disorders Therapeutics Market, The US, Treatment Usage Patterns (Millions), 2002-2010
  • Table 14: Musculoskeletal Disorders Therapeutics Market, The US, Treatment Usage Patterns (Millions), 2010-2017
  • Table 15: Musculoskeletal Disorders Therapeutics Market , Top Five Countries of Europe, Revenue ($bn), 2002-2010
  • Table 16: Musculoskeletal Disorders Therapeutics Market , Top Five Countries of Europe, Revenue Forecasts ($bn), 2010-2017
  • Table 17: Musculoskeletal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue by Country ($bn), 2002-2010
  • Table 18: Musculoskeletal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue by Country ($bn), 2010-2017
  • Table 19: Musculoskeletal Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2010
  • Table 20: Musculoskeletal Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2010-2017
  • Table 21: Musculoskeletal Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (Millions), 2002-2010
  • Table 22: Musculoskeletal Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (Millions), 2010-2017
  • Table 23: Musculoskeletal Disorders Therapeutics Market, Japan, Revenue ($bn), 2002-2010
  • Table 24: Musculoskeletal Disorders Therapeutics Market, Japan, Revenue Forecasts ($bn), 2010-2017
  • Table 25: Musculoskeletal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2010
  • Table 26: Musculoskeletal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010-2017
  • Table 27: Musculoskeletal Disorders Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2002-2010
  • Table 28: Musculoskeletal Disorders Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2010-2017
  • Table 29: Rheumatoid Arthritis Therapeutics Market, Global, Revenue ($bn), 2002-2010
  • Table 30: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecast ($bn), 2010-2017
  • Table 31: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010
  • Table 32: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017
  • Table 33: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
  • Table 34: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment($), 2010-2017
  • Table 35: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010
  • Table 36: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2017
  • Table 37: Osteoporosis Therapeutics Market, Global, Revenue ($bn), 2002-2010
  • Table 38: Osteoporosis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017
  • Table 39: Osteoporosis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010
  • Table 40: Osteoporosis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017
  • Table 41: Osteoporosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
  • Table 42: Osteoporosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017
  • Table 43: Osteoporosis Therapeutics Market, Global, Treatment Usage Pattern (Millions), 2002-2010
  • Table 44: Osteoporosis Therapeutics Market, Global, Treatment Usage Pattern (Millions), 2010-2017
  • Table 45: Osteoarthritis Therapeutics Market, Global, Revenue ($bn), 2002-2010
  • Table 46: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017
  • Table 47: Osteoarthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010
  • Table 48: Osteoarthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017
  • Table 49: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
  • Table 50: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017
  • Table 51: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2002-2010
  • Table 52: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2010-2017
  • Table 53: Low Back Pain Therapeutics Market, Global, Revenue ($bn), 2002-2010
  • Table 54: Low Back Pain Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017
  • Table 55: Low Back Pain Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010
  • Table 56: Low Back Pain Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017
  • Table 57: Low Back Pain Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
  • Table 58: Low Back Pain Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017
  • Table 59: Low Back Pain Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2002-2010
  • Table 60: Low Back Pain Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2010-2017
  • Table 61: Muscular Dystrophy Therapeutics Market, Global, Revenue ($m), 2002-2010
  • Table 62: Muscular Dystrophy Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017
  • Table 63: Muscular Dystrophy Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010
  • Table 64: Muscular Dystrophy Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2017
  • Table 65: Muscular Dystrophy Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
  • Table 66: Muscular Dystrophy Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017
  • Table 67: Muscular Dystrophy Therapeutics Market, Global, Treatment Usage Patterns (000's), 2002-2010
  • Table 68: Muscular Dystrophy Therapeutics Market, Global, Treatment Usage Patterns (000's), 2010-2017
  • Table 69: Musculoskeletal Disorders Therapeutics Market, Global, Pipeline Analysis, NDA Filed Molecules, July 2011
  • Table 70: Musculoskeletal Disorders Therapeutics Market, Global, Pipeline Analysis, Phase III, July 2011
  • Table 71: Musculoskeletal Disorders Therapeutics Market, Global, Pipeline Analysis, Phase II, July 2011
  • Table 72: Musculoskeletal Disorders Therapeutics Market, Global, Pipeline Analysis, Phase I, July 2011
  • Table 73: Musculoskeletal Disorders Therapeutics Market, Global, Pipeline Analysis, Preclinical Phase, July 2011
  • Table 74: Musculoskeletal Disorders Therapeutics Market, Global, Pipeline Analysis, Discovery Phase, July 2011
  • Table 75: Musculoskeletal Disorders Therapeutics Market, Global, M&A, 2009-2011
  • Table 76: Musculoskeletal Disorders Therapeutics Market, M&A Deals, By Value ($m) 2009-2011
  • Table 77: Musculoskeletal Disorders Therapeutics Market, Co-development, By Geography, 2009-2011
  • Table 78: Musculoskeletal Disorders Therapeutics Market, Licensing Deals, By Geography, 2009-2011

List of Figures

  • Figure 1: Musculoskeletal Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017
  • Figure 2: Musculoskeletal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
  • Figure 3: Musculoskeletal Disorders Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2017
  • Figure 4: Musculoskeletal Disorders Therapeutics Market, Global, Diseased Population (millions), 2002-2017
  • Figure 5: Musculoskeletal Disorders Therapeutics Market, Global, Treatment Seeking Population (millions), 2002-2017
  • Figure 6: Musculoskeletal Disorders Therapeutics Market, Global, Diagnosed Population (millions), 2002-2017
  • Figure 7: Musculoskeletal Disorders Therapeutics Market, Global, Prescription Population (millions), 2002-2017
  • Figure 8: Musculoskeletal Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017
  • Figure 9: Musculoskeletal Disorders Therapeutics Market, The US, Revenue Forecasts ($bn), 2002-2017
  • Figure 10: Musculoskeletal Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2002-2017
  • Figure 11: Musculoskeletal Disorders Therapeutics Market, The US, Treatment Usage Patterns (Millions), 2002-2017
  • Figure 12: Musculoskeletal Disorders Therapeutics Market , Top Five Countries of Europe, Revenue Forecasts ($bn), 2002-2017
  • Figure 13: Musculoskeletal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue by Country ($bn), 2002-2017
  • Figure 14: Musculoskeletal Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017
  • Figure 15: Musculoskeletal Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (Millions), 2002-2017
  • Figure 16: Musculoskeletal Disorders Therapeutics Market, Japan, Revenue ($bn), 2002-2017
  • Figure 17: Musculoskeletal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2017
  • Figure 18: Musculoskeletal Disorders Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2002-2017
  • Figure 19: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017
  • Figure 20: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017
  • Figure 21: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Segmentation
  • Figure 22: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
  • Figure 23: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2017
  • Figure 24: Rheumatoid Arthritis Therapeutics Market, Global, Diseased Population (Millions), 2002-2017
  • Figure 25: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Seeking Population (Millions), 2002-2017
  • Figure 26: Rheumatoid Arthritis Therapeutics Market, Global, Diagnosed Population (Millions), 2002-2017
  • Figure 27: Rheumatoid Arthritis Therapeutics Market , Global, Prescription Population (Millions), 2002-2017
  • Figure 28: Musculoskeletal Disorders Therapeutics Market, Global, Rheumatoid Arthritis Pain, Treatment Algorithm
  • Figure 29: Rheumatoid Arthritis, Market Drivers and Barriers, 2010-2017
  • Figure 30: Osteoporosis Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017
  • Figure 31: Osteoporosis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017
  • Figure 32: Osteoporosis Therapeutics Market, Global, Branded and Generics Share, 2010 & 2017
  • Figure 33: Osteoporosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
  • Figure 34: Osteoporosis Therapeutics Market, Global, Treatment Usage Pattern (Millions), 2002-2017
  • Figure 35: Osteoporosis Therapeutics Market, Global, Diseased Population (Millions), 2002-2017
  • Figure 36: Osteoporosis Therapeutics Market, Global, Treatment Seeking Population (Millions), 2002-2017
  • Figure 37: Osteoporosis Therapeutics Market, Global, Diagnosed Population (Millions), 2002-2017
  • Figure 38: Osteoporosis Therapeutics Market , Global, Prescription Population (Millions), 2002-2017
  • Figure 39: Musculoskeletal Disorders Therapeutics Market, Global, Osteoporosis, Treatment Algorithm
  • Figure 40: Osteoporosis, Market Drivers and Barriers, 2010-2017
  • Figure 41: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017
  • Figure 42: Osteoarthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017
  • Figure 43: Osteoarthritis Therapeutics Market, Global, Branded and Generics Share, 2010 & 2017
  • Figure 44: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
  • Figure 45: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2002-2017
  • Figure 46: Osteoarthritis Therapeutics Market, Global, Diseased Population (Millions), 2002-2017
  • Figure 47: Osteoarthritis Therapeutics Market, Global, Treatment Seeking Population (Millions), 2002-2017
  • Figure 48: Osteoarthritis Therapeutics Market, Global, Diagnosed Population (Millions), 2002-2017
  • Figure 49: Osteoarthritis Therapeutics Market, Global, Prescription Population (Millions), 2002-2017
  • Figure 50: Musculoskeletal Disorders Therapeutics Market, Global, Osteoarthritis, Treatment Algorithm
  • Figure 51: Osteoarthritis, Market Drivers and Barriers, 2010-2017
  • Figure 52: Low Back Pain Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017
  • Figure 53: Low Back Pain Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017
  • Figure 54: Low Back Pain Therapeutics Market, Global, Branded and Generics Share (%), 2010 & 2017
  • Figure 55: Low Back Pain Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
  • Figure 56: Low Back Pain Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2002-2017
  • Figure 57: Low Back Pain Therapeutics Market, Global, Diseased Population (Millions), 2002-2017
  • Figure 58: Low Back Pain Therapeutics Market, Global, Treatment Seeking Population (Millions), 2002-2017
  • Figure 59: Low Back Pain Therapeutics Market, Global, Diagnosed Population (Millions), 2002-2017
  • Figure 60: Low Back Pain Therapeutics Market, Global, Prescription Population (Millions), 2002-2017
  • Figure 61: Musculoskeletal Disorders Therapeutics Market, Global, Low Back Pain, Treatment Algorithm
  • Figure 62: Low Back Pain, Market Drivers and Barriers, 2010-2017
  • Figure 63: Muscular Dystrophy Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017
  • Figure 64: Muscular Dystrophy Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017
  • Figure 65: Muscular Dystrophy Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
  • Figure 66: Muscular Dystrophy Therapeutics Market, Global, Treatment Usage Patterns (000's), 2002-2017
  • Figure 67: Muscular Dystrophy Therapeutics Market, Global, Diseased Population (000's), 2002-2017
  • Figure 68: Muscular Dystrophy Therapeutics Market, Global, Treatment Seeking Population (000's), 2002-2017
  • Figure 69: Muscular Dystrophy Therapeutics Market, Global, Diagnosed Population (000's), 2002-2017
  • Figure 70: Muscular Dystrophy Therapeutics Market, Global, Prescription Population (000's), 2002-2017
  • Figure 71: Musculoskeletal Disorders Therapeutics Market, Global, Muscular Dystrophy, Treatment Algorithm
  • Figure 72: Muscular Dystrophy, Market Drivers and Barriers, 2010-2017
  • Figure 73: Musculoskeletal Disorders Therapeutics Market, Global, R&D Pipeline by Indication (%), 2011
  • Figure 74: Musculoskeletal Disorders Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011
  • Figure 75: Musculoskeletal Disorders Therapeutics Market, Global, SWOT - Abbott Laboratories, 2010
  • Figure 76: Musculoskeletal Disorders Therapeutics Market, Global, SWOT - Johnson & Johnson, 2010
  • Figure 77: Musculoskeletal Disorders Therapeutics Market, Global, SWOT - Amgen Inc., 2010
  • Figure 78: Musculoskeletal Disorders Therapeutics Market, Global, SWOT - Pfizer, 2010
  • Figure 79: Musculoskeletal Disorders Therapeutics Market, Global, SWOT - Eli Lilly, 2010
  • Figure 80: Musculoskeletal Disorders Therapeutics Market, Global, Deals by Indications, 2009-2011
  • Figure 81: Musculoskeletal Disorders Therapeutics Market, M&A Deals, By Value ($m) 2009-2011
  • Figure 82: Musculoskeletal Disorders Therapeutics Market, M&A Deals, By Geography, 2009-2011
  • Figure 83: Musculoskeletal Disorders Therapeutics Market, Co-development, By Indications, 2009-2011
  • Figure 84: Musculoskeletal Disorders Therapeutics Market, Licensing Deals, By Geography, 2009-2011
  • Figure 85: GBI Research Market Forecasting Model
新聞稿

全球肌肉骨骼系統疾病治療藥物市場的學名藥比例將持續增加,邁向穩定成長

2012年02月13日

Global Information Inc.開始代理銷售由GBI Research,所發行的調查報告「Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014 (全球肌肉骨骼疾病治療藥物的市場(到2017年為止))」。

全球的肌肉骨骼系統疾病市場在2002年至2010年間,以年複合成長率(CAGR)5.7%成長,而2010年的市場規模約為334億美元。

2010年至2017年間,預估將以CAGR 7.3%成長,而在2017年的市場規模將達到548億美元。

全球的肌肉骨骼系統疾病治療藥物市場在2010年至2017年間,將會有一系列的專利期滿,其中也包含Cymbalta (duloxetine HCl) 和Celebrex (celecoxib)等最暢銷的醫藥品。

現在的市場產品線將來會有所成長,但是將無法完全抵消與學名藥競爭所造成的影響。

肌肉萎縮症為最廣為所知的肌肉骨骼系統疾病之一,不過,卻沒有可使用於此疾病的已認可治療選項。因此,學名藥在市場上的比例逐漸持續擴大。

image1

image2

全球肌肉骨骼疾病治療藥物的市場(到2017年為止)是由出版商GBI Research在2012年01月06日所出版的。這份市場調查報告書包含159 Pages 價格從美金3500起跳。

Back to Top
;